Vorasidenib is the first oral targeted therapy authorised for the treatment of adults and paediatric patients aged 12 years and older with Grade 2 IDH-mutant gliomas, who have undergone surgical ...

Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer IDH-mutant brainstem gliomas have a characteristic clinical and radiographic phenotype.

Treatment with vorasidenib significantly improved progression free survival compared with placebo. The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib) for the treatment of adult ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first approval of ...

The emergence of vorasidenib, the first targeted therapy for certain gliomas with IDH mutations, has ignited a wave of excitement in both patient and physician spaces. But following the approval, some ...

IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront treatment. By adding a newer, targeted therapy aimed at the underlying IDH ...

The FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The drug -- an IDH1 and IDH2 inhibitor - ...

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 ...

A research team in Japan has developed an innovative system that can accurately detect genetic mutations in the brain tumor within just 25 minutes. Genetic mutations are crucial markers for diagnosis ...